Patents by Inventor Monsef Benkirane
Monsef Benkirane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210405026Abstract: A method for the evaluation of the efficacy of a drug aiming to eradicate a cellular reservoir of mammalian cells infected with a mammalian immunodeficiency virus, the method including: a) quantifying, the presence of lymphocyte cells expressing a CD32 differentiation marker on their surface; and b) concluding that the drug is efficient to eradicate the cellular reservoir of mammalian cells infected with the mammalian immunodeficiency virus when lymphocyte cells expressing a CD32a differentiation marker are absent.Type: ApplicationFiled: August 18, 2021Publication date: December 30, 2021Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef BENKIRANE, Gaël PETITJEAN, Benjamin DESCOURS
-
Publication number: 20210325391Abstract: A method for the evaluation of the efficacy of a drug aiming to eradicate a cellular reservoir of mammalian cells infected with a mammalian immunodeficiency virus, the method including: a) quantifying, the presence of lymphocyte cells expressing a CD89 differentiation marker on their surface; and b) concluding that the drug is efficient to eradicate the cellular reservoir of mammalian cells infected with the mammalian immunodeficiency virus when lymphocyte cells expressing a CD89 differentiation marker are absent.Type: ApplicationFiled: May 7, 2021Publication date: October 21, 2021Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
-
Patent number: 11125751Abstract: The use of differentiation marker CD32 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD32 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD32 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody in treatment.Type: GrantFiled: September 30, 2017Date of Patent: September 21, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef Benkirane, Gael Petitjean, Benjamin Descours
-
Patent number: 11054424Abstract: The present invention relates to the use of a nucleic acid molecule encoding a first reporter gene, bordered by at least one first pair and one second pair of sequences targeting a site-specific recombinase in order to detect cells of a mammal infected with a virus responsible for an immunodeficiency.Type: GrantFiled: December 17, 2015Date of Patent: July 6, 2021Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Monsef Benkirane, Gael Petitjean
-
Patent number: 11041858Abstract: The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.Type: GrantFiled: September 30, 2017Date of Patent: June 22, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef Benkirane, Gael Petitjean, Benjamin Descours
-
Publication number: 20200031925Abstract: The use of differentiation marker CD32 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD32 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD32 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody in treatment.Type: ApplicationFiled: September 30, 2017Publication date: January 30, 2020Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
-
Publication number: 20190219577Abstract: The use of differentiation marker CD89 for the detection of cellular reservoirs of a mammalian immunodeficiency virus. Also the use of the differentiation marker CD89 for making a prognosis, diagnosing a remission, and evaluating the efficacy of treatment of the mammalian immunodeficiency. A multi-specific antibody that recognizes both at least one epitope of CD89 and at least one characteristic of the lymphocyte cells, a composition including the antibody, and the use of the antibody for treatment.Type: ApplicationFiled: September 30, 2017Publication date: July 18, 2019Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Monsef BENKIRANE, Gael PETITJEAN, Benjamin DESCOURS
-
Publication number: 20170350889Abstract: The present invention relates to the use of a nucleic acid molecule encoding a first reporter gene, bordered by at least one first pair and one second pair of sequences targeting a site-specific recombinase in order to detect cells of a mammal infected with a virus responsible for an immunodeficiency.Type: ApplicationFiled: December 17, 2015Publication date: December 7, 2017Applicant: Centre National De La Recherche Scientifique (CNRS)Inventors: Monsef Benkirane, Gael Petitjean
-
Patent number: 9439923Abstract: The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.Type: GrantFiled: November 26, 2009Date of Patent: September 13, 2016Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)Inventors: Monsef Benkirane, Robinson Triboulet, Christine Chable-Bessia, Yamina Bennasser, Daniel Latreille, Oussama Meziane, Pascal Barbry, Bernard Mari, Jacques Reynes
-
Publication number: 20150276760Abstract: The present invention relates to a method for screening a compound capable of inhibiting the Notch1 transcriptional activity. The present invention also relates to compounds useful in the prevention or treatment of cell proliferative diseases and disorders associated with overexpression and/or activation of Notch1.Type: ApplicationFiled: October 4, 2012Publication date: October 1, 2015Inventors: Yves Levy, Monsef Benkirane, Ahmad Yatim
-
Publication number: 20140010839Abstract: The present invention relates to an in vitro method of screening for candidate compounds capable of being used for the preventative and/or curative treatment of a disease caused by a retrovirus in which the candidate compound which modulates the expression and/or the activity of the SAMHD1 protein is identified as a candidate compound capable of being used for the preventative and/or curative treatment of a disease caused by a retrovirus. The invention also relates to a vaccine composition and an immunogenic composition, comprising i) an inhibitor of the expression and/or of the activity of the SAMHD1 protein and ii) at least one antigen of a retrovirus.Type: ApplicationFiled: March 23, 2012Publication date: January 9, 2014Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Monsef Benkirane, Nadine Laguette, Bijan Sobhian
-
Publication number: 20120053223Abstract: The present invention relates to at least one nucleic acid (i) comprising or consisting of or (ii) encoding a nucleic acid comprising or consisting of, a sequence selected from the group consisting of: 1) SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and 2) a sequence derived from SEQ ID NO: 1 to 4 by substitution deletion or insertion of at least one nucleotide, provided that a nucleic acid consisting of the sequence derived from SEQ ID NO: 1 to 4 is liable to induce HIV-1 expression in latent HIV-1-infected cells, for use as a medicament, in particular for treating retrovirus infections.Type: ApplicationFiled: November 26, 2009Publication date: March 1, 2012Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)Inventors: Monsef Benkirane, Robinson Triboulet, Christine Chable-Bessia, Yamina Bennasser, Daniel Latreille, Oussama Meziane, Pascal Barbry, Bernard Mari, Jacques Reynes
-
Method for inducing a specific rnai activity in cells and nucleic acids for carrying out said method
Publication number: 20070082864Abstract: A method for inducing activity of a specific RNAi into eukaryote cells in which the TAT protein and a nucleic acid coding for a nucleotide sequence comprising the sense and antisense sequences of an RNAi of interest are introduced, which sense and antisense sequences are separated by a separating nucleotide sequence coding for a sequence comprising at least the minimal TAR sequence recognized by the TAT protein, which transcribed separating sequence and the TAT protein form a complex that inhibits the activity of the RNAi of interest, and the activity of the RNAi is induced by withdrawing the TAT protein.Type: ApplicationFiled: October 19, 2004Publication date: April 12, 2007Inventors: Annick Harel-Bellan, Slimane Ait-Si-Ali, Monsef Benkirane